Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amersham’s Metastron (Strontium-89)

Executive Summary

Injectable cancer pain drug is being launched June 28 at a list price of $1,850 for a 4 mCi single-dose vial. One dose, delivered in an outpatient procedure, "usually is effective for an average of six months." Metastron, approved by FDA on June 18, ("The Pink Sheet" June 21, T&G-1) will be promoted to urology and medical oncology specialists by Zeneca and to nuclear medicine, radiopharmacy, and radiation oncology experts by Amersham, under a worldwide co-promotion agreement.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS022833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel